Highlights

  • Medibank Private (ASX:MPL) reported FY26 Revenue growth and higher underlying earnings.
  • Underlying NPAT increased to A$636.8 million, while the final Dividend rose 6.7%.
  • Medibank Health continued expanding, with segment revenue increasing 30.8%.
  • The company maintained a strong Capital position with a capital coverage ratio of 1.9 times.

Medibank Private (ASX:MPL) reported FY26 results highlighting higher profit, increased Shareholder returns and continued growth across its health services division. The company’s shares were trading at AUD 4.95, up 5.10% on 21 August 2026.

The company’s FY26 results, released on 20 August 2026, showed growth across revenue and Earnings while also highlighting ongoing challenges within the core Health Insurance business, including Margin pressure and competitive conditions.

For investors assessing Medibank Private (ASX:MPL), the key areas of focus remain health insurance margins, policyholder growth, expansion of Medibank Health and capital management.

What is happening with Medibank?

Medibank Private is Australia’s largest private health insurer, with operations spanning health insurance and broader health services.

The company’s FY26 results highlighted a mixed performance, with steady growth from its core insurance operations and stronger expansion across Medibank Health.

The company continues focusing on balancing its established insurance Franchise with growth opportunities in healthcare services.

Latest company developments

Medibank reported FY26 group revenue of A$9.12 billion, representing a 5.9% increase.

Underlying net profit after tax reached A$636.8 million, while statutory NPAT increased to A$638.7 million.

The board declared a final dividend of 10.9 cents per share, taking the full-year dividend to 19.2 cents per share, up 6.7%.

Health Insurance remained the company’s largest contributor, with operating profit increasing 3.8% to A$769.8 million.

The Health Insurance Operating Margin remained at 9.0%, while resident policyholders increased by 22,100 units, or 1.1%. The ahm Brand recorded stronger growth, increasing 2.4%, compared with 0.6% growth for the Medibank brand.

Medibank Health continued to expand, with revenue increasing 30.8% to A$634.8 million and segment profit rising 31.3% to A$100.7 million. The growth was supported by acquisitions including Better Medical.

The company’s final dividend represented an 83% payout ratio, within its targeted 75–85% range.

What do the numbers say?

Medibank’s FY26 performance reflected steady earnings growth, although the underlying trends differed across Business segments.

Underlying NPAT increased 2.9%, indicating more moderate earnings growth compared with the increase in statutory profit.

Health Insurance remained the core earnings contributor, with resident premium revenue increasing 4.5% to A$8.27 billion. However, the flat operating margin indicates that claims Inflation and competitive pressures continue affecting profitability.

Medibank Health was the stronger growth area, with revenue increasing more than 30%. However, the segment’s gross margin declined 180 basis points to 51.5% due to changes in business mix.

The company maintained a capital coverage ratio of 1.9 times, supporting financial flexibility and shareholder returns.

For FY27, management expects broadly consistent resident health insurance gross margins and approximately 25% growth in Medibank Health segment profit, including a full-year contribution from Better Medical.

What could drive the shares from here?

Health insurance margin stability remains a key Factor for Medibank Private (ASX:MPL).

Improved policyholder growth, effective premium adjustments and management of claims inflation could support earnings performance.

Continued growth across Medibank Health, including successful integration of acquisitions, may strengthen the company’s Diversification strategy.

Capital management remains another area of focus, with the company maintaining a strong capital position and a high payout ratio.

Industry conditions, including regulatory settings and private health participation trends, will also influence future performance.

Risks investors should watch

Margin pressure remains a key risk for Medibank, particularly if claims inflation continues exceeding premium growth.

Competition within the private health insurance market may affect pricing power and member retention.

Regulatory changes around premium approvals and industry settings could influence earnings outcomes.

The Medibank Health expansion strategy carries integration and execution risks, particularly as acquisitions become a larger contributor to growth.

Investment income remains exposed to financial market conditions and Interest Rate movements.

Cybersecurity and data protection risks remain important considerations given the sensitive nature of healthcare information.

Investor takeaway

Medibank Private (ASX:MPL) delivered a FY26 result showing steady revenue growth, higher profit, increased dividends and continued expansion across its health services business.

The company’s core health insurance operations remain stable but face ongoing margin pressures, while Medibank Health provides a growth avenue through diversification.

The key factors ahead include health insurance margin trends, policyholder growth, execution of health services expansion and future capital management decisions.